Establishment Labs (ESTA)
Develops breast implants, tissue expanders, and a minimally invasive enhancement procedure.
Something off on this page? Send us feedback.
Motiva implants, the Motiva Flora tissue expander, and Mia form a breast-aesthetics and reconstruction portfolio. Manufacturing in Costa Rica supports international commercialization and a U.S. business operating under FDA PMA requirements.
Motiva Implants, the Motiva Flora tissue expander, and the Mia minimally invasive procedure serve breast aesthetics and reconstruction. The company develops, manufactures, and commercializes these products within a women’s-health focus.
Manufacturing is based in two Costa Rican facilities, while the principal executive office is in Austin. Motiva expanded from international sales to China and began U.S. commercial sales after FDA PMA approval.
U.S. Motiva sales operate under the FDA PMA framework, including registry participation and post-approval studies. Product development, manufacturing compliance, and regulatory requirements shape the operating model for surgeon use.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | Citigroup | Upgrade | ||
| Aug 7, 2026 | BTIG | Reiterate | Rating: —Target: $86 | Target: $103 |
| Aug 6, 2026 | Needham | Reiterate | Rating: —Target: $84 | Target: $95 |
| Aug 6, 2026 | Canaccord Genuity | Target | Target: $85 | Target: $105 |
| Jul 15, 2026 | Mizuho Securities | Target | Target: $70 | Target: $105 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $71.2M · Total debt $263.7M · Total assets $351.9M · Shareholders' equity $21.6M
- Revenue
- $67.5M
- Operating income
- −$4.3M
- Net income
- −$11.7M
No dividends on record.
| Institutions | 95.62% | 28.14M shares | |
|---|---|---|---|
| 210 holders · as of Jun 30, 2026 | |||
| Insiders | 12.77% | 3.76M shares | |
| 13 holders · as of Aug 26, 2026 | |||
| Adds to | 108.39% | ||
29.43M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 108.39%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
JW Asset Management, LLCInstitution | 9.15% | 2.69M | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 9.02% | 2.66M | as of Jun 30, 2026 |
Qatar Investment AuthorityInsider | 8.12% | 2.39M | filed May 13, 2025 |
BlackRock, Inc.Institution | 5.38% | 1.58M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 5.21% | 1.53M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 28, 2026 | JW Asset Management, LLC | other: See footnote 3 | −65,100 | $72.89 |
| May 27, 2026 | JW Asset Management, LLC | other: See footnote 3 | −113 | $72.50 |
| May 26, 2026 | JW Asset Management, LLC | other: See footnote 3 | −25,320 | $74.39 |
| May 21, 2026 | JW Asset Management, LLC | 10 percent owner | −16,999 | $71.40 |
| May 20, 2026 | JW Asset Management, LLC | 10 percent owner | −3,580 | $70.56 |
- AbbVie
Natrelle implants overlap in breast augmentation and reconstruction
- Johnson & Johnson
MENTOR overlaps in implants and breast-tissue expansion
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Establishment Labs | $70.24 | −0.06% | $1.99B | — | — | 8.1 | +31.7% |
| AbbVie | $265.32 | +0.02% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Johnson & Johnson | $269.17 | −0.04% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Median | 52.9 | 20.1 | 6.9 | +8.4% |